A new post-hoc analysis of a Phase II clinical trial suggests that a lifetime of norovirus exposure creates an immunological blueprint that determines how well older adults respond to modern vaccines.
Researchers examined neutralizing antibody responses in participants aged 60 and older who received a bivalent GI.1/GII.4c virus-like particle vaccine. Before vaccination, the strongest immune defenses were directed against archaic GII.4 variants that circulated decades ago, with substantially weaker responses to modern strains.
Following vaccination, antibody levels surged. However, the boost preferentially amplified pre-existing immunity tied to ancestral variants and the closely related GII.4c vaccine component.
Antigenic cartography confirmed that vaccination enhanced cross-reactive responses, but distinct differences between old and new viral clusters persisted. Antibody levels remained above baseline for many variants one year later, with durable protection specifically noted against the vaccine-matched GII.4c strain.
The findings strongly support the concept of immune imprinting in norovirus defense. Researchers suggest future vaccines may need to pair ancestral strains-which recall broad, pre-existing immunity-with antigenically novel variants to outpace viral evolution.